Wednesday, July 8, 2026

Patent intelligence · US

US 12036266

Activatable cytokine polypeptides and methods of use thereof

granted A61KA61K2239/31A61K2239/38A61K2239/48
Status granted
Pipeline programs 2
Years to expiry 18
Applicant portfolio 10
Patent details — US 12036266
Jurisdiction
US
Status
granted
Grant date
Jul 16, 2024
Expiration
Jul 11, 2044
Claims
19
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/48
View on Google Patents ↗

Quick answer

US 12036266 (Activatable cytokine polypeptides and methods of use thereof) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Jul 16, 2024. Expires Jul 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K35/17, A61K38/00

More from Werewolf Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12275769

    Activatable interleukin 12 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Expires Apr 10, 2045

    granted
  2. US 12076371

    Activatable cytokine polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Expires Aug 29, 2044

    granted
  3. US 11981716

    Activatable interleukin-2 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Expires May 9, 2044

    granted
  4. US 11739132

    Separation moieties and methods of use thereof

    Werewolf Therapeutics, Inc. · Expires Aug 24, 2043

    granted
  5. US 11535658

    Activatable interleukin-2 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Expires Dec 22, 2042

    granted
  6. US 11453710

    Activatable interleukin 12 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Expires Sep 22, 2042

    granted
  7. US 11352403

    Activatable interleukin-2 polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Expires Jun 2, 2042

    granted

Frequently asked questions

What is US patent 12036266?

US 12036266 (Activatable cytokine polypeptides and methods of use thereof) is held by Werewolf Therapeutics, Inc.. Status: granted. Granted Jul 16, 2024. Expires Jul 11, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12036266?

Werewolf Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.

When does US 12036266 expire?

Our index shows an expiration date of Jul 11, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.